Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Ingelsson

Showing results (1-10 of 217) with videos related to

Pageof 22
Sort By:
Frontiers in Neuroscience|September 23, 2016
Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body DisordersMartin Ingelsson
Movement Disorders : Official Journal of the Movement Disorder Society|April 1, 2022
Targeted Gene Therapy to Treat Disorders of the Central Nervous SystemSanskriti Sasikumar, Martin Ingelsson
Molecular Diagnosis & Therapy|October 29, 2024
Correction to: Molecular Therapeutics in Development to Treat Alzheimer's DiseaseMaria Carmela Tartaglia, Martin Ingelsson
Annals of Medicine|October 10, 2002
Disordered proteins in dementiaMartin Ingelsson, Bradley T Hyman
Molecular Diagnosis & Therapy|September 24, 2024
Molecular Therapeutics in Development to Treat Alzheimer's DiseaseMaria Carmela Tartaglia, Martin Ingelsson
Methods in Molecular Biology (Clifton, N.J.)|June 11, 2018
Generation and Characterization of Stable α-Synuclein OligomersLeire Almandoz-Gil, Martin Ingelsson, Joakim Bergström
Open Heart|September 14, 2021
Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findingsLars Lind, Martin Ingelsson, Johan Sundstrom, et al.
Biochimica Et Biophysica Acta|December 24, 2004
Transcriptional and conformational changes of the tau molecule in Alzheimer's diseaseBradley T Hyman, Jean C Augustinack, Martin Ingelsson
Cellular and Molecular Neurobiology|May 2, 2023
Altered Distribution of SNARE Proteins in Primary Neurons Exposed to Different Alpha-Synuclein ProteoformsEmma Brolin, Martin Ingelsson, Joakim Bergström, et al.
Acta Neuropathologica|August 4, 2020
The existence of Aβ strains and their potential for driving phenotypic heterogeneity in Alzheimer's diseaseHeather H C Lau, Martin Ingelsson, Joel C Watts
Pageof 22

Showing results (1-10 of 217) with videos related to

Sort By:
Pageof 22
Frontiers in Neuroscience|September 23, 2016
Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body DisordersMartin Ingelsson
Movement Disorders : Official Journal of the Movement Disorder Society|April 1, 2022
Targeted Gene Therapy to Treat Disorders of the Central Nervous SystemSanskriti Sasikumar, Martin Ingelsson
Molecular Diagnosis & Therapy|October 29, 2024
Correction to: Molecular Therapeutics in Development to Treat Alzheimer's DiseaseMaria Carmela Tartaglia, Martin Ingelsson
Annals of Medicine|October 10, 2002
Disordered proteins in dementiaMartin Ingelsson, Bradley T Hyman
Molecular Diagnosis & Therapy|September 24, 2024
Molecular Therapeutics in Development to Treat Alzheimer's DiseaseMaria Carmela Tartaglia, Martin Ingelsson
Methods in Molecular Biology (Clifton, N.J.)|June 11, 2018
Generation and Characterization of Stable α-Synuclein OligomersLeire Almandoz-Gil, Martin Ingelsson, Joakim Bergström
Open Heart|September 14, 2021
Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findingsLars Lind, Martin Ingelsson, Johan Sundstrom, et al.
Biochimica Et Biophysica Acta|December 24, 2004
Transcriptional and conformational changes of the tau molecule in Alzheimer's diseaseBradley T Hyman, Jean C Augustinack, Martin Ingelsson
Cellular and Molecular Neurobiology|May 2, 2023
Altered Distribution of SNARE Proteins in Primary Neurons Exposed to Different Alpha-Synuclein ProteoformsEmma Brolin, Martin Ingelsson, Joakim Bergström, et al.
Acta Neuropathologica|August 4, 2020
The existence of Aβ strains and their potential for driving phenotypic heterogeneity in Alzheimer's diseaseHeather H C Lau, Martin Ingelsson, Joel C Watts
Pageof 22